Alumis
Derrick Richardson is a seasoned professional with extensive experience in leadership roles within the fields of project management and people and culture. Currently serving as Senior Vice President of People and Culture at Alumis since January 2022, Derrick previously held significant positions including Vice President and Head of People and Culture and Vice President and Head of Program and Portfolio Management at the same organization. Derrick's prior experience includes roles at Bristol Myers Squibb as Therapeutic Area Head for Cardiovascular Late Stage Project Management and at MyoKardia as Executive Director and Head of Project Management. Derrick also held consulting roles and leadership positions at Genentech, Nitinol Devices & Components, AbbVie, Invuity, NeoGuide Systems, Conor Medsystems, and Cordis Corporation, Johnson & Johnson. Derrick holds a Bachelor of Science in Product Design Engineering from Stanford University and a Master of Engineering in Mechanical Engineering from Cornell University.
Alumis
2 followers
At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.